Prognosis of the disease
DISEASE PROGRESSION
Because the follow‐up time was short and no patient died during the study, no overall survival analyses could be performed. Four patients in the ICd group exhibited disease progression after 5,8,17 or 19 cycles, respectively, whereas five patients in the Id group exhibited progression after 2, 3, 7,12 or 15 cycles, respectively, (Figure Progression‐free survival (PFS) by ICd and Id treatment. PFS rates at the endpoint were 78.9% and 70.6% in ICd and Id, respectively. Kaplan–Meier analysis, 